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Abstract: The currently hyped expectation of personalized medicine is often associated with just achieving the
information technology led integration of biomolecular sequencing, expression and histopathological bioimaging
data with clinical records at the individual patients’ level as if the significant biomedical conclusions would be its
more or less mandatory result. It remains a sad fact that many, if not most biomolecular mechanisms that translate
the human genomic information into phenotypes are not known and, thus, most of the molecular and cellular data
cannot be interpreted in terms of biomedically relevant conclusions. Whereas the historical trend will certainly be
into the general direction of personalized diagnostics and cures, the temperate view suggests that biomedical
applications that rely either on the comparison of biomolecular sequences and/or on the already known
biomolecular mechanisms have much greater chances to enter clinical practice soon. In addition to considering the
general trends, we exemplarily review advances in the area of cancer biomarker discovery, in the clinically relevant
characterization of patient-specific viral and bacterial pathogens (with emphasis on drug selection for influenza and
enterohemorrhagic E. coli) as well as progress in the automated assessment of histopathological images. As
molecular and cellular data analysis will become instrumental for achieving desirable clinical outcomes, the role of
bioinformatics and computational biology approaches will dramatically grow.
Author summary: With DNA sequencing and computers becoming increasingly cheap and accessible to the
layman, the idea of integrating biomolecular and clinical patient data seems to become a realistic, short-term
option that will lead to patient-specific diagnostics and treatment design for many diseases such as cancer,
metabolic disorders, inherited conditions, etc. These hyped expectations will fail since many, if not most
biomolecular mechanisms that translate the human genomic information into phenotypes are not known yet and,
thus, most of the molecular and cellular data collected will not lead to biomedically relevant conclusions. At the
same time, less spectacular biomedical applications based on biomolecular sequence comparison and/or known
biomolecular mechanisms have the potential to unfold enormous potential for healthcare and public health. Since
the analysis of heterogeneous biomolecular data in context with clinical data will be increasingly critical, the role of
bioinformatics and computational biology will grow correspondingly in this process.
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When will genome sequences, expression profiles
and computer vision for bioimage interpretation
be routinely used in clinical medicine?
There is apparently no doubt for anyone that modern life
science research based on the new high-throughput tech-
nologies most prominently represented by genomic se-
quencing together with the increasingly powerful and, at
the same time, affordable information technology products
will dramatically change healthcare. The main idea behind
these expectations is that the new availability of data char-
acterizing the patients’ individuality at the level of genome,
biomolecules and gene/protein networks together with
evermore powerful diagnostic, mainly imaging tools at the
histological, anatomical and physiological levels allow ever
finer stratification of the patients’ conditions once the mo-
lecular data is integrated with clinical data and, finally, it
will lead to the design of personalized treatment regimes.
Unfortunately, the discussion in the media has become
hyped with expectations increasingly getting out of touch
with the progress that both biomedical science [1] and
healthcare at the ground can deliver in the short and
medium term. In this discussion and, to some extent, re-
view article, we try to analyze what are major trends in
computational biology and bioinformatics that support
the advance towards stratified and personalized medicine
and what are the fundamental and some of the proced-
ural barriers on the path towards the solution of major
healthcare problems such as infections, cancer, metabolic
and neurodegenerative diseases, familial disorders, etc.
The article is structured as follows: In the section The
hype around genomics and proteomics technologies in
the healthcare context and fundamental reasons calling
for a temperate view, we look into the general develop-
ments that fuel the expectations of revolutionary change
in health care and public health; we talk about several
roadblocks that have been removed on the path towards
personalized/stratified medicine and the possible role of
bioinformatics and computational biology in this process.
We also emphasize what are the reasons why many of
the expectations will not materialize in the short- to
medium-term time frame. Section Management of
innovation cycles of high-throughput technologies and
the role of bioinformatics in this process is dedicated to
issues that arise when bioinformaticians/computational
biologist actually penetrate into the actual health care
provision system under the condition when the applica-
tion of new computational analysis methods and evalu-
ation protocols is not really routine.
In sections Bioinformatics moving towards clinical on-
cology: biomarkers for cancer classification, early diag-
nostics, prognosis and personalized therapy (cancer
biomarkers), Sequence-structure-function relationships
for pathogenic viruses and bacteria and their role in com-
bating infections (infectious diseases) and Impact of
Bioimage Informatics on Healthcare (computerized
histopathology), we exemplarily discuss and partially re-
view the progress in application areas that have already
or will likely benefit in the near future from interaction
with bioinformatics/computational biology approaches.
Although often histologically similar, increasingly more
cancer subtypes are getting characterized at the level of
the specific, individual biomolecular mechanisms that
drive the growth of the tumor cell population and, thus,
are essentially understood as different diseases. Cancer
biomarkers are critical for diagnosis, classification, prog-
nosis and therapy progress evaluation in this concept
(section Bioinformatics moving towards clinical oncol-
ogy: biomarkers for cancer classification, early diagnos-
tics, prognosis and personalized therapy).
Due to their small genome and the possibility to suc-
cessfully deduce phenotype properties from mutations,
viral and bacterial pathogens are thankful objects for com-
putational biology analysis in the clinical context (in con-
trast to the situation with higher eukaryotes such as
human; section Sequence-structure-function relationships
for pathogenic viruses and bacteria and their role in com-
bating infections). As example, we review in depth the
clinically relevant characterization of patient-specific influ-
enza viral infections. We also show that genome analysis
of enterohemorrhagic E.coli allows selecting existing FDA
approved drugs for treatment.
In section Impact of Bioimage Informatics on Health-
care, we review advances in the automated assessment
of histopathological and, to a minor extent, other med-
ical images. Possibly, these developments in this area
might have a non-spectacular but a very profound im-
pact on health care delivery very soon since the pro-
blems to overcome are more of the engineering type and
not of fundamentally scientific origin.
The hype around genomics and proteomics technologies
in the healthcare context and fundamental reasons
calling for a temperate view
Several roadblocks towards the goal of stratified/perso-
nalized medicine have disappeared very recently. The
spectacular improvement of nucleic acid sequencing
technologies lead to a reduction in costs, both in time
and money, at a scale that can only be described as jaw-
dropping for the observer. Whereas the first full human
genome sequencing absorbed about 3 billion USD in the
USA alone and it took about a decade to be accom-
plished [2], recently offered machines such as Ion Pro-
ton™ Sequencer (Life Technology) or HiSeq™ 2500
(Illumina) [3] move these numbers rather close towards
1000 USD and a single day. And this appears not to be
the endpoint of the technology development with more
progress to be expected in the medium-term future.
Naturally, dreams about all kinds of sequencing
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applications, especially, in clinical contexts and with af-
fluent patients start sprouting. To note, the progress of
nucleic acid sequencing is just the most eye-catching; es-
sentially, it hides dramatic progress also in many other
areas and high-throughput technologies such as expres-
sion profiling, histopathological image processing, etc.
We need to acknowledge, that for life sciences, where,
historically, getting at least some verifiable, quantified
data for their biological system of study was a major dif-
ficulty and the setup of experiments and not the analysis
of the measurement absorbed most of the intellectual
capacity [4], the current deluge of quantified data is
really a game changer and puts theoretical analysis
detached from experimentation into general importance
for the field for the first time.
The second major change is in IT itself. The older
among the list of authors still remember their times as
PhD students when the access to mainframe machines
was cumbersome and heavily restricted and a good desk-
top computer with graphical interface in the late eight-
ies/early nineties had the price of a luxury sports car.
Today, for nominally the same money, one can equip
several research teams if not a small institute with com-
puter clusters (e.g., a 64 core computer trades for just
about 10000 USD), storage systems and network tools
that are more powerful than necessary for about 90% of
the tasks in computational biology. Thus, computing
and storage opportunities are essentially no longer the
limiting factor for life science research compared with
just a decade or even a few years ago.
The hype currently accumulating around the new op-
portunities with sequencing and other high-throughput
technologies, maybe, is sensed most directly in the
entrepreneurs’ and scientists’ comments compiled by
Bio-IT World at its WWW page dedicated to the 10th
anniversary of its own launch [5]. Although there are
some minority cautionary notes, one cannot get away
with the general impression that concluding from mo-
lecular data to clinically important statements is mainly
seen as a problem of the scale of data generation. It is
expected that the IT-centric efforts of integrating
patient-specific sequencing, expression, tissue imaging
data with clinical information (whatever might be the
exact meaning of this “data integration”; just putting
everything into one electronic database) will inevitably
lead to significant healthcare outcomes in terms of per-
sonalized medicine.
This surprisingly optimistic view remembers the eu-
phoria that, ten years ago, accompanied the presentation
of the first draft of the human genome caused by the an-
ticipation that “Genetic prediction of individual risks of
disease and responsiveness to drugs will reach the med-
ical mainstream in the next decade or so. The develop-
ment of designer drugs, based on a genomic approach to
targeting molecular pathways that are disrupted in dis-
ease, will follow soon after” [6]. With hindsight, we
know that the progress in the last decade has not
reached the promises, not even nearly [1,7]. The hype in
the media is also in suspicious contrast to the recent at-
tempt of certain pharmaceutical companies to slash
down their own research force and to promote the idea
of open innovation, i.e., essentially unloading research
efforts, costs and research risks into the public sphere.
Whereas the general developmental trend appears cor-
rectly predicted, the devil is in the detail and the serious
disagreement is about timescales and in which areas/
applications the healthcare breakthroughs from genom-
ics and other technologies are more likely in the time
closer to us. Moving from the scientific laboratory to ac-
tual healthcare is also associated with a myriad of add-
itional issues besides the scientific task itself. Apparently
boring questions such as predictive power, robustness,
standardization, availability and reliability of the new
methods in conditions of routine application in regular
hospitals, clinics and in the out-patient context by pos-
sibly scientifically insufficiently trained personnel be-
come urgent. This includes the comparison of the new
methods with more traditional, tested approaches not
only from the viewpoint of medical science but also
cost-wise (in terms of money and working time for tests
and data analyses). Since considerable economic interest
is associated with the upcoming healthcare revolution
not only from IT equipment and healthcare solution
providers but also from charlatans who, for example, try
to sell life style advice derived from the customers’ own
genome sequence already today, it is important to get
the discussion away from the level of fairy tale and
hyped promises and to assess the current state of the art
realistically.
Besides the costs, the most important argument
against having genome sequencing and expression profil-
ing from every patient at present is the fact that the
overwhelming part of this data cannot be interpreted
into biologically and/or medically significant conclu-
sions. Today, ever faster sequencing leads foremost to
ever faster growing amounts of non-understood se-
quence data. To note, we need to know about the bio-
molecular mechanisms that translate the genome
sequence into phenotypes when we wish to interfere ra-
tionally at the molecular level. As elaborated elsewhere,
the biological functions of about every second human
gene are not well or even completely not known [1]. The
whole mystery of non-coding RNA function is hardly
scratched upon; yet, we know that many, also non-
protein-coding regions of the genome are actively
transcribed and this expression influences important
biological processes [8,9]. Maybe, it was one of the most
important insights from the whole human genome
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sequencing project that we can estimate now how much
human biology at the molecular level we do not know,
namely most likely (much) more than 50% [1]. To just
search for correlations between phenotypic, including
clinical conditions and genomic changes will appear in-
sufficient because of several reasons: 1) the path relating
genome features and phenotype is extremely complex in
many cases. 2) The statistical significance criteria will re-
quire impossibly large cohorts. 3) Rationally designed
therapy without mechanistic insight is problematic.
Given the pace of progress in the area of biomolecular
mechanism discovery during the last decade, it is
expected that it will take another century until we will
understand our own genome. Presumably, scientific,
technological and social factors will kick in that will ac-
celerate the advance [1]; yet, it is clear that this is not a
short term issue.
Most likely, biomedical applications that rely either on
the comparison of DNA or, generally, nucleic acid
sequences, without necessarily understanding their bio-
logical meaning or on the biomolecular mechanisms that
are already more or less known have the greatest likeli-
hood to achieve importance for healthcare, public health
and biotechnology. To the first class of applications be-
long methods for the identification of the human indivi-
dual’s origin and identity, be it in the forensic, genealogy
or legal context, but also the diagnostics of hereditary
diseases and the characterization of food items in terms
of quality and origin. With regard to the latter class of
applications, those diseases that require the investigation
of less complex gene networks and biomolecular
mechanisms will have better chances to benefit from se-
quencing, expression profiling and histopathological
imaging informatics than those with more complex
mechanisms. In this light, the perspectives of fighting
infections or cancer are more promising than, for ex-
ample, those of battling obesity since energy metabolism
appears to be one of the most complexly regulated sys-
tems in humans.
In this context, does the sequencing of patients’ DNA
in a large scale make sense? In several countries, for ex-
ample in Norway [10], programs are being implemented
that aim exactly at realizing this vision, the sequencing
of the patients’ genomes and of their cancers. It appears
to us that, at this stage, the move may be justified for
small, rich countries that have the necessary capacity to
finance an extensive follow-up fundamental research ef-
fort to study the newly collected data since, in many
cases, the clinical outcome for the specific patient might
be negligible at present. Thus, sequencing, expression
profiling, etc. make sense in a clinical setup where the
data can enter into a research environment for proper,
non-standard data analysis and where, beyond potential
benefit for the specific patient, these expensive laboratory
investigations can have serendipitous consequences for
the scientific knowledge gain that might benefit many
other future patients.
Management of innovation cycles of high-throughput
technologies and the role of bioinformatics in this
process
In addition to fundamental scientific problems with bio-
molecular mechanisms discovery, we need to emphasize
that high-throughput technologies such as nucleic acid
sequencing are far from mature. The renewal cycle
involves maximally a couple of years and it might be
already tomorrow that, due to some unexpected
innovation, the equipment purchased yesterday is hope-
lessly out of date even if the machines continue to look
shiny. Since the new generation of sequencing, expres-
sion profiling and other high-throughput technologies
tend to generate the biological data at much lower costs
and with higher accuracy than their predecessors, it does
not make sense to produce more data than can be prop-
erly analyzed within a reasonably short time frame; fu-
ture researcher will rather look at regenerated data
produced with newer technologies available then instead
of reviving old data files.
Even for dedicated research institutions with rich bud-
gets, it remains a financial problem to participate in
every step of technology development. It is not just the
purchase of new pieces of equipment, but also the estab-
lishment of subsequent data analysis pipelines, software
replacements and the training of the respective staff or
even the hiring of new types of professionals. The latter
issues might create more headache than the sequencer
purchase itself.
Many clinical labs attached to research and other top-
end hospitals around the world are thinking about how
to prepare for a swift increase in genomics and proteo-
mics analysis needs. Ever since their emergence in 2005,
next-generation sequencing (NGS) technologies have
proven revolutionary research tools in a variety of scien-
tific disciplines of the life sciences. NGS technologies are
now increasingly being applied in clinical environment,
which is partly due to the emergence of novel and effi-
cient sequencing protocols and partly to the appearance
of smaller, less expensive sequencing platforms. The pos-
sibilities of applying NGS in clinical research ranges
from full human genome profiling [11], microbiome pro-
filing [12] to biomarker discovery, stratification of
patients for clinical trials, prediction of drug response
and patient diagnosis. Such applications often involve
targeted re-sequencing of genes of clinical relevance
whereby not the entire genome is sequenced, only a few
dozen PCR-amplified regions or known disease-related
genes. These genes harbor diagnostic or causative muta-
tions of diseases including indels and single nucleotide
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polymorphisms. Individual genes have previously been
interrogated in clinical testing using traditional techni-
ques such as Sanger sequencing however NGS technolo-
gies have already begun to supplant the previous tools of
choice in these areas, offering increased speed and
throughput with reduced running costs.
Targeted re-sequencing in the clinical context presents
specific requirements and new challenges also for bio-
informatics which is aggravated by new computational
needs of fast changing sequencing platforms. Just to
mention one problem, that of multiplexing: simultan-
eous analyses of many patients for many diseases require
accurate and unequivocal identification of many persons
and many genes within an ensemble of many hundred
thousand reads. Molecular bar-coding makes this pos-
sible, but standard bioinformatics tools are not ready to
handle bar-coding information [13,14].
Clinical labs seek the advice of bioinformaticians
regarding what kind of software to use. The usual stand-
ard answer is to use the current best of genomics soft-
ware. Unfortunately, it is often found that these tools are
not even always capable of doing the clinical application
job, for example detecting specific mutation types. The
reason is simple: Genome aligners were designed to map
short reads to a whole genome, i.e., finding relatively
strong similarities in a background of weak or minimal
similarities. This scenario has called for specific speed-
up solutions and approximations, many of which may
not necessarily be true for amplicon sequencing proto-
cols. So, clinicians usually face two problems: i) Buy an
expensive hardware and non-transparent, and more
often than not, very computer time-consuming commer-
cial software from the platform vendor, or ii) seek advice
from trained bioinformaticians who may point them to
academic tools developed for genome analysis, but not
necessarily suitable for amplicon sequencing. The solu-
tion is not easy. Platform vendors cannot be blamed for
proposing a technically sound solution which, for the
moment, has no chances to follow the exponential
growth of clinical analysis needs. So, it is the task of fu-
ture bioinformatics projects to develop accurate and
flexible solutions for clinical applications.
Bioinformatics moving towards clinical oncology:
biomarkers for cancer classification, early
diagnostics, prognosis and personalized therapy
Losses of human lives and sufferings as a result of can-
cer remain one of the critical obstacles in prolonging ac-
tive human life span. Worldwide, cancers are responsible
for one in eight deaths [15]. In Singapore, cancers are
the major causes of mortality and accounts for about
28.5% of all deaths [16]. In our present understanding,
cancer is a disease involving genetic changes in certain
cell populations that lead to cellular reprogramming and
uncontrolled cell division; in turn, the formation of a
malignant mass can create a variety of clinical symp-
toms. The huge individual genome variation and diver-
sity of cellular phenotypes in cancers often complicates
clinical detection, classification, prognosis and treatment
of patients. In fact, histologically similar cancers do not
necessarily represent the same disease due to differences
in the biomolecular mechanisms leading finally to simi-
lar clinical outcomes. Consequently, among the list of 10
most important human diseases, the pharmacotherapy
efficacy of cancer is very low except for a few rare sub-
types [17]. The progress in the early diagnostics/detec-
tion and therapy of many cancers is very slow. For
instance, for the past 30 years, ovarian cancers (OC)
mortality rate has remained very high and unchanged,
despite considerable efforts directed toward this disease.
Current clinical oncology needs (i) improvement of
disease classification, (ii) increased specificity and sensi-
tivity of early detection instruments/molecular diagnos-
tics systems, (iii) improved disease risk profiling/
prediction, (iv) improvement of cancer therapeutic
methods including next generation drugs with higher
specificity and lowered toxicity (ideally, inhibitors of the
exact biomolecular mechanisms that drive individual
cancer growth) and generally more stratified or even
personalized therapies, (v) understanding of the anti-
cancer immune response, (vi) adequate monitoring and
rehabilitation during post-treatment recovery period and
(viii) patients’ social adaptation.
At present, there are two main lines of support for
clinical oncology from the side of computational biology
fuelled by data generated by genomics and proteomics
high-throughput technologies. On the one hand, genome
and RNA sequencing as well as expression profiling of
cancer biopsy samples opens the possibility to under-
stand the biomolecular mechanisms that are behind the
malignant transformation in the individual patient’s
tumor case. On the other hand, the status of biomarkers
can be measured and used to provide more accurate
diagnostics of a specific cancer type, prognosis and se-
lection of personalized therapy.
Hunting after cancer mutations in a clinical setup
The problems associated with large-scale sequencing
and expression profiling of cancers need to be seen from
two sides. Whereas the technical aspects of correct se-
quence and expression profile determination from gen-
erally miniscule biopsy amounts are considerable but
manageable (see a recent review of some of the IT and
bioinformatics aspects [18]), the evaluation of the data
in terms of clinically relevant conclusions for the specific
patient is presently impossible in most cases and the
clinically relevant effort is centered more around the
question whether the actual patient happens to carry a
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cancer that belongs to one of the better understood sub-
types. At the same time, sequencing and expression pro-
filing of carefully selected cohorts of cancer patients are
of immeasurable value for biomedical research aimed
studying yet unknown biomolecular mechanisms.
Technically, analyzing somatic mutations in complex
diseases such as cancer is particularly challenging since
the mutant alleles can be easily diluted below detection
thresholds due to the presence of wild type non-tumor
DNA and the inherent genetic heterogeneity of the
tumor itself. The problem is further aggravated by the
limited amount of DNA (1-100 ng) available from biop-
sies on the one hand, and the clinical sample prepar-
ation, on the other: For example, clinical samples
fixation in formalin randomly breaks DNA into 200-400
bp long fragments.
The current gold standard method tries to circumvent
these problems by applying targeted PCR amplification
to 100-200 bp long target sequences which is followed
by Sanger sequencing of the PCR amplicons. Next gen-
eration sequencing (NGS) platforms such as the 454
FLX Genome analyzer (Roche) or Ion Torrent Personal
Genome Machine (Life Technology), offer important
advantages due to their extremely high (1000-10000
fold) sequence coverage. Thus, sensitivity as compared
to Sanger sequencing is increased. This is very important
for detecting low frequency mutations, which makes
NGS an attractive option for diagnostic sequencing.
For clinical analysis of the transcriptome, deep se-
quencing technologies (e.g. RNA-seq, etc.) allow detect-
ing low abundant RNA transcripts. Many classes of
these transcripts (e.g., long non-coding RNAs) play es-
sential regulatory roles in cancer development and can
potentially be used for clinical sub-typing, detection,
prognosis and therapy design of cancers. Detection of
the rare genome aberrations and low-abundant tran-
scripts in cancers and in human body fluids might be
important. However, clinical studies of such data re-
quire development of appropriated biomedical research
infrastructure, collection of large patients’ cohorts, man-
agement of well-coordinated interdisciplinary research
projects, dynamical and integrative databases, novel IT
solutions and massive data analyses within a computa-
tional biology research effort.
Another advantage of NGS technology is its ability to
deal with parallel sequencing of multiple genes. The
widely respected white paper of the American Society of
Clinical Oncology [19] suggested that all targeted drugs
should be registered based on the molecular profile in-
dependently from the tumor type. Recently, researchers
of the Massachusetts General Hospital argued that sim-
ultaneous analysis of 12 genes is useful for the diagnosis
of lung cancer [20]. Therefore, there is a clinical need
for targeted re-sequencing of dozens of genes in each
cancer patient. There are several, commercially available
multiplex re-sequencing assays in clinical use today. A
typical analysis for cancer targets may require PCR-
based re-sequencing of 10 to 1500, mainly exon-derived
amplicons selected from 10 to 400 genes, and a mini-
mum amount of 10 ng DNA [21].
Biomarkers for cancer classification: mutations in
signaling proteins
A biomarker is a traceable biochemical substance that is
informative about the status of a disease or medical con-
dition. For practical purposes, it is sufficient to show a
close correlation between the occurrence of the bio-
marker and the cancer type and development in model
systems and in clinical trials. Yet, the likelihood of the
biomarker actually being associated with the cancer sub-
type considered is dramatically increased if the bio-
marker plays a role in the biomolecular mechanisms
driving the cancer and not just in some secondary or
tertiary effects of cancer growth. However, discovery of
reliable diagnostic, prognostic and drug response cancer
biomarkers faces big challenges due to patient hetero-
geneity, small sample sizes, and high data noises.
A couple of cancer subtypes well-characterized mech-
anistically have recently seen spectacularly successful
treatment. Mutations in signaling proteins have been
found to drive cells into the cancer state and the design
of drugs that specifically bind to these mutated forms
have been shown to suppress cancer development. For
the drugs to be applied, a companion diagnostic test is
necessary to verify whether the potential patient has in-
deed a cancer driven by the target supposed. As a rule,
this will dramatically shrink the number of patients but
the selected ones have a high chance to receive benefits
from the treatment. Three cases illuminating the trend
towards mutation-specific targeting drugs are reviewed
in some detail below.
Several forms of chronic myelogenous leukemia
(CML) and gastrointestinal stromal tumors (GISTs) are
characterized by the Philadelphia chromosome, a chromo-
somal translocation, and the subsequent fusion of genes
bcr and abl. As a result, the tyrosine kinase abl is locked
in its active signaling state and affecting the down-
stream pathways Ras/MapK (increased proliferation due
to increased growth factor-independent cell growth),
Src/Pax/Fak/Rac (increased cell motility and decreased
adhesion), PI/PI3K/AKT/BCL-2 (suppression of apop-
tosis) and JAK/STAT (driving proliferation). The inhibi-
tor Imatinib (STI571, Gleevec) inhibits bcr-abl and, as a
result, an originally fatal disease is transformed into a
chronically manageable one [22]. The same inhibitor is
also active for some sequence variants of c-kit and
PDGF-R (platelet-derived growth factor receptor) and,
thus, can be applied in a handful of other cancers. Since
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application of the drug is essentially selectively killing
sensitive cells, strains with resistant mutations survive
and it might require the application of other batteries of
drugs to bring these strains down, too [23].
Another case with some success are melanoma sub-
types with the B-RAF mutation V600E that can be trea-
ted with vemurafenib (PLX4032, RG7204) [24,25]. In
melanomas with mutant B-RAF (V600E), the drug inhi-
bits specifically B-RAF (V600E) monomers. Since the
ERK signaling inhibition is tumor-specific, these RAF
inhibitors have a broad therapeutic index and a remarkable
clinical activity in patients with melanomas that harbor
the respective B-RAF mutant (V600E). However, resist-
ance invariably emerges, for example via alternative spli-
cing. The version p61 B-RAF (V600E) shortened by exons
4-8 shows enhanced dimerization in cells with low levels
of RAS activation and ERK signalling is resistant to the
RAF inhibitor [25].
Certain EGFR (epidermal growth factor receptor, an-
other tyrosine kinase) driven cancers of breast, lung,
pancreas, etc. are sensitive to gefitinib (Iressa) or erloti-
nib (Tarceva). The EGFR class includes Her1 (erb-B1),
Her2 (erb-B2), and Her 3 (erb-B3). The EGFRs are
hyper-activated due to a mutation in the tyrosine kinase
domain and this leads to inappropriate activation of the
anti-apoptotic Ras signalling cascade, eventually result-
ing in uncontrolled cell proliferation [26].
Biomarkers for cancer classification: up-regulated genes
The literature on cancer biomarkers is enormous and it
is beyond this review to be comprehensive. Here, we
focus on developments with our authors’ involvement.
Lung adenocarcinoma (AC) is the most common type
of lung cancer which is the leading cause of cancer
deaths in the world. The genetic mechanisms of the
early stages and lung AC progression steps are poorly
understood. Currently, there are no clinically applicable
gene tests for early diagnosis and lung AC aggressiveness
assessment. Recently, authors of this review (VK et al.)
suggested a method for gene expression profiling of pri-
mary tumours and adjacent tissues (PT-AT) based on a
new rational statistical and bioinformatics strategy of
biomarker prediction and validation, which could pro-
vide significant progress in the identification of clinical
biomarkers of lung AC. This approach is based on the
extreme class discrimination (ECD) feature selection
method that identifies a combination/subset of the most
discriminative variables (e.g. expressed genes) [27]. This
method includes a paired cross-normalization (CN) step
followed by a modified sign Wilcoxon test with multi-
variate adjustment carried out for each variable. Analysis
of paired Affymetrix U133A microarray data from 27
AC patients revealed that 2,300 genes can discriminate
AC from normal lung tissue with 100% accuracy. Our
finding reveals a global reprogramming of the transcrip-
tome in human lung AC tissue versus normal lung tissue
and for the first time estimates a dimensionality of space
of potential lung AC biomarkers. Cluster analysis applied
to these genes identified four distinct gene groups. The
genes related to mutagenesis, specific lung cancers, early
stage of AC development, tumour aggressiveness and
metabolic pathway alterations and adaptations of cancer
cells are strongly enriched in the discriminative gene set.
26 predicted AC diagnostic biomarkers (including SPP1
and CENPA genes) were successfully validated on qRT-
PCR tissue array. The ECD method was systematically
compared to several alternative methods and proved to
be of better performance [27]. Our findings demonstrate
that the space of potential clinical biomarker of lung
cancers is large; many dozens of combined biomarkers/
molecular signatures are possible. This finding suggests
that further improvement of computational prediction
and feature selection methods is necessary in conjunc-
tion with systematic integration of massive and complex
data analysis.
Similar computational approaches applied on breast
cancer patients’ expression data allowed important new
insights into molecular and clinical classification, tumor
aggressiveness grading and identification of novel tumor
sub-types. Current statistical approaches for biomarker
selection and signature extraction were extended by
developing a hybrid univariate/multivariate approach,
combining rigorous statistical modeling and network
analysis [28]. In this approach, single survival-significant
genes can be identified and used to generate important
cancer related gene networks. The method also allows
estimating the synergistic effect of two or several genes
belonging to the same or different networks on the
patients’ survival. With this analysis, we generated and
evaluated several related signature sets which are super-
ior to traditional clinical prognostic markers and existing
breast cancer classifications [28-30]. The final groupings
have significantly different p53 mutation status, tumor
aggressiveness grading and metastasis events. Most im-
portantly, it could be shown that the intermediate class
of G2 breast cancers does not have a justification at the
level of gene expression. The G2 cases are shown to be
either G1-like or G3-like. This implies that G2 patients
with a G3-like expression profile are recommended to
receive the more aggressive treatment reserved for G3
patients.
Currently, using clinical and molecular markers does
not provide specific and reliable ovarian cancer (OC)
patients’ stratification, prognosis and treatment response
prediction. High-grade epithelial ovarian serous carcin-
oma (HG-EOC), a major type of OC, is poorly detected.
At the molecular level, the tumors frequently exhibit
altered expressions of many hundreds and thousands
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features at genome, transcriptome and proteome levels.
The specific and reliable biomarkers of this complex
disease and appropriate therapeutic targets have not
been defined yet. Similar computational approaches as
described above in the cases of lung and breast cancers
have been used to derive expression signatures for OC
and they were found to include the EVI1 gene [31].
It is also notable that non-coding RNAs can also be
used as biomarkers [32]. To conclude, the identification
of reliable diagnostic, prognostic and drug response-
related biomarkers for cancer requires integrative data
analysis and understanding of the molecular and cellular
basis of genome loci and gene expression and pathways.
Sequence-structure-function relationships for
pathogenic viruses and bacteria and their role in
combating infections
Whereas the discussion above has highlighted that
sequence-function relationships are not well understood
and this status will continue for a while, the situation for
the small genomes of pathogenic viruses and bacteria is
considerably more promising. Their genome size is
much smaller (from a handful of genes in the case of
viruses to maximum a few thousand genes for bacteria)
and their physiology is much more completely under-
stood at the level of biomolecular mechanisms. For ex-
ample, there is no gene in the influenza virus where at
least some mechanistic aspect of its molecular and cellu-
lar function is known; a stark contrast to the situation
for the human genome where about half of the genes
still await their at least initial characterization [1] and
even the compilation of the complete proteome is not in
sight [33].
With sequencing getting increasingly cheaper and effi-
cient, it became possible to explore the full genome of
the set of strains that is actually invading the patient’s
body. This is important since, to evade the patient’s im-
mune system, the pathogen mutates and one or several
of the mutants might find the weak spots of the patient
and propagate. This allows not only designing efficient
patient-specific treatment strategies, for example by de-
ducing certain drug resistances theoretically from the
pathogen’s genomic sequence before even trying actually
the respective drug in the treatment. It provides also
much better options for epidemiology and public health
since each strain can be individually determined and,
thus, the actual spread of the pathogen can be traced
geographically and in real time. Measures for preventing
and combating epidemics can be designed more ration-
ally and with lower costs for social and economic life.
Most attention with regard to rationally designed strat-
egies for fighting infection so far has been directed to-
wards the acquired immunodeficiency syndrome (AIDS)
caused by the human immunodeficiency virus (HIV) and
this can rightly be considered a success story for compu-
tational biology. A previously absolutely fatal disease has
been transformed into a chronic illness with high quality
of life and, for many patients, with apparently zero viral
blood counts. Not only have all the drugs against AIDS
used in the multi-drug cocktail for high active antiretro-
viral therapy (HAART) been rationally designed against
structures of HIV proteins to interfere into the well-
studied life cycle of the virus [34]. New drugs appear all
the time and provide new treatment opportunities for
patients harboring strains resistant against the standard
cocktails [35]. Sophisticated knowledge-based thera-
peutic algorithms [36] are available to treat AIDS
patients optimally depending on the mutation spectrum
within the patient’s viral load [37,38].
Similar strategies are useful for other pathogens that
try to evolve away from the attack of antibiotics/antiviral
therapy or the immune system’s efforts. Staphylococcus
aureus causing a wide range of infection from skin to
post-operative wound infections has great adaptive
potential and can generate forms (best known as
methicillin-resistant Staphylococcus aureus - MRSA)
widely resistant against many available antibiotics. Exact
determination of the molecular epidemiology with
multi-locus sequence typing and other methods can be
the basis for an optimized antibiotics selection for more
efficient therapy [39].
In the following, we explore how classical bioinformatics
aimed at studying biomolecular sequences and structures
can impact infection medicine in context with the influ-
enza virus and the enterohemorrhagic E. coli pathogens.
Genome sequence studies of the influenza virus and
public health
Besides the occasional pandemics, recurrent seasonal in-
fluenza and its ongoing evolution has always been an
important topic concerning public health. Whenever a
new flu strain emerges and threatens to circle the globe,
health authorities and clinicians need to know the char-
acteristics of the new virus including virulence, drug
susceptibility and vaccine efficacy. The recent swine flu
pandemic from 2009 is an excellent example how com-
putational methods can provide crucial support not only
in the early molecular characterization [40-42] but also
to follow the still ongoing evolution of the virus. Modern
sequencing technology and increased preparedness
resulted in a significant worldwide increase of institu-
tions and hospitals that can generate molecular sequence
data from patient samples. But when the patient-specific
strain sequences are available after sequencing ordered
by hospitals or ministries, it appears that the institution
cannot properly handle them. The expertise for the subse-
quent steps of computational analysis to connect the geno-
type to possible phenotypes is often sparse. Bioinformatics
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can be used to rapidly screen influenza sequences for po-
tentially interesting mutations, for example, through com-
parative genomics, 3D structural modeling, literature text
mining and plotting geo-temporal occurrence patterns for
epidemiological significance.
While this sounds exciting, are we really in a state that
we can reliably predict relevant phenotypic changes from
sequence mutations? First, the influenza genome is small
and codes for only 10-13 proteins all of which are well
characterized in their functions and there exists a mechan-
istic understanding how they work together as well as how
they interact with the infected host. Second, there is wide
interest in influenza research and the amount of available
sequences, crystal structures, experimental data and asso-
ciated literature is enormous which allows transferring in-
formation and annotations if very closely related strains are
compared. For example, the typical Tamiflu resistance mu-
tation H274Y in the neuraminidase protein has the same
effect on equivalent positions in seasonal H3N2, old sea-
sonal H1N1, pandemic H1N1, avian H5N1, etc.
But what can be said about “new” mutations? In the
second wave of the 2009 H1N1 pandemic, a Norwegian
team reported a high frequency of a new hemagglutinin
mutation D222G in severe cases [43]. The power of bio-
informatics for linking genotype to phenotype for influ-
enza mutations can be shown for this example, as within
a few hours from first reports of the mutation one could
find a possible mechanistic explanation on how this mu-
tation could possibly exert its severity using computa-
tional tools and databases alone. The first obstacle is the
numbering, different groups prefer to use old seasonal
H3N2 based numberings also for H1N1 pandemic strains
but it is important to know that D222G is actually corre-
sponding to the mutation D239G in the literal sequence
numbering of circulating pandemic strains which is neces-
sary to find and count appearances of this mutation in
available influenza surveillance sequences. This can easily
be resolved computationally by aligning with respective
reference strains with defined numbering. Sequence
alignments to strains with known structure can also be
used to build homology models and find the corresponding
position of the mutation in the 3D structure. It turns out
that D222/239G was located within the receptor binding
pocket which determines the type of sugar-linked sialic
acids recognized on human host cells but the precise
effects on substrate specificity is still challenging to predict
in detail by docking and modeling alone. Being able to
switch between numbering schemes is also important to
find prior work on related mutations in the literature. In-
deed, a corresponding position in avian H1N1 has previ-
ously been investigated [44] as mutation G225D which is
exactly equivalent to the new D222/225/239G but with
inverted direction. The paper had found that G at this pos-
ition is associated with preference for α2-3 avian-like re-
ceptor specificity while D would bind better to α2-6
human-like receptors. By analogy, it was possible to deduce
that the new D222/225/239G mutation in the pandemic
H1N1 could possibly shift the receptor preference to
avian-like α2-3 receptors. The next important additional
hint from the literature was that also humans have some
α2-3 receptors but they are found deeper in the lungs, not-
ably in the bronchiolae [45]. Finally, everything comes to-
gether and a hypothetical mechanism on how the new
mutation could be related to severity is apparent where the
D239G would change the receptor specificity to allow
infections deeper in the lungs (Figure 1). More than a year
later, this exact mechanism of the D222/225/239G muta-
tion was studied in detail [46] and the experiments verified
what could be suggested already much earlier by computa-
tional and literature analysis by a bioinformatics expert
within a few hours. Many of the functions described here,
have now been implemented in the WWW-based FluSur-
ver that can accept patient-specific virus genome informa-
tion and generate a clinical relevance report automatically
(SMS et al., to be published).
There are many more examples where Bioinformatics
analysis helped to elucidate phenotypic roles of new influ-
enza mutations such as marker mutations of new variants
Figure 1 The link between an influenza virus mutation and the altered course of infection. Schematic representation showing how a
single viral amino acid mutation (right, red balls) can affect host cell receptor (blue balls) interaction, which can alter viral localization and where
the infection takes place, which in turn can affect severity and symptoms for the patient (left). A thorough understanding of the effects of
mutations on biological mechanisms is also important for other human diseases such as cancer as well as patient-specific response to different
treatments. Attribution of images: The 3 left-most images of the composed figure are public domain or under free-to-use licenses at Wikimedia
commons from the following sources: patient body and organ [118] and infected cell [119].
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rising in occurrence [47], changes in hemagglutinin surface
epitopes [48] and glycosylation sites as well as detect
known [49] and novel [50-52] mutations in the neuramin-
idase drug binding pocket that alter antiviral drug efficacy.
While the wealth of prior work on influenza is crucial for
the ability to make relevant computational predictions, it
shows that, with a concerted effort, similar successes may
be achieved in other areas of high interest.
Conclusions from the sequence of the enterohemorrhagic
O104:H4 E. coli strain
Next generation sequencing has dramatically brought
down the cost of genome sequencing but the current
reality is that there usually is a long way from the initial
genomic data to information relevant for clinicians.
However, there are exceptions. When an enterohemor-
rhagic O104:H4 E. coli strain caused a major outbreak in
Germany [53] in 2011, the genome sequence was rapidly
available through next generation sequencing [54]. At
the same time, the Robert Koch Institute provided the
microbial characterization including the clinically im-
portant antibiotic susceptibility profile [55]. In principle,
the information if a specific antibiotic drug is effective
against an organism should be encoded in its genome by
the presence of the known target gene of the respective
drug as well as the absence of associated drug resistance
factors. Clearly, the prerequisite for computationally de-
riving an antibiotic susceptibility profile depends not
only on the availability of the whole genome but also
sufficiently complete annotation data for drug targets
and resistance mechanisms of closely related strains or
organisms. Since E. coli and related bacteria have been
widely studied before in this regard, we show here that
one can computationally identify antibiotic drugs that,
potentially, can effectively target a new pathogen with
available genome, such as the enterohemorrhagic O104:
H4 E. coli strain. The steps to achieve this are essentially
routine bioinformatics work but typically not easily ac-
cessible to clinicians.
First, the available genome sequences (http://www.ncbi.
nlm.nih.gov/Traces/wgs/?val=AFOB01) were searched with
BLASTX [56] for close to identical sequence matches
against a database of known drug targets from DrugBank
[57]. Requiring at least 97% sequence identity of the E. coli
sequences to the proteins known to be drug targets ensures
that also their structure will be highly similar and hence
should represent the same drug binding properties. Sec-
ond, we repeat the sequence search but this time against a
database of known drug resistance factors from ARDB [58]
requiring a lower threshold of at least 60% identity to con-
servatively pick up also more remote similarities to possible
resistance factors. Third, we use a Perl script to parse the
hits from the BLAST outputs as well as the drug target
and resistance annotation data from the two databases and
finally identify the list of drugs for which a known target
gene was found in the genome but no respective associated
resistance factor.
In order to validate the results, we compared our com-
putational antibiotic susceptibility profile with the ex-
perimental results. To our positive surprise, 15 out of 25
experimentally tested antibiotics were also covered by
the existing databases and could, hence, be assessed
through our computational workflow. The identity
thresholds for the two sequence searches described
above have been selected to produce the best possible
match with the experimental data. Table 1 shows that
the in silico approach correctly assigns resistance or sen-
sitivity for 13 of the 15 antibiotics. In detail, the new
bacterial strain was correctly predicted to be sensitive to
7 antibiotics and resistant to 6 drugs from the list. The
only two cases of a mismatch from the prediction with
the clinical experimental result are interesting and dis-
cussed below.
The first case is the combination drug Piperacillin/
Tazobactam which we flag as sensitive but the Robert
Koch Institute as resistant. Sequence searches identified
a TEM-1 metallo beta-lactamase in O104:H4 E. coli
which causes resistance to penicillins (including Pipera-
cillin) by degrading them but we also find that there
exists a specific inhibitor against TEM-1 metallo beta-
lactamases, Tazobactam, which is given in combination
with Piperacillin to inhibit the beta-lactamase and,
Table 1 Predicted potentially effective drugs against
enterohemorrhagic E. coli
Antibiotic Exp. Comp.
Piperacillin/Tazobactam R* S
Cefoxitin R R
Ceftazidim R R
Cefpodoxim R R
Imipenem S S
Meropenem S S
Amikacin S S
Gentamicin S S
Kanamycin S S
Tobramycin S S
Streptomycin R R
Tetracyclin R R
Nitrofurantoin S S
Trimethoprim/Sulfamethoxazol R R
Fosfomycin S R
Experimentally measured (Exp.) versus computationally predicted (Comp.)
antibiotics susceptibility profile. R . . . resistant; S. . . sensitive; * . . . defined as
resistant (AES VITEK). Prediction and experimentally determined results
coincide except for two cases (Piperacillin/Tazobactam and Fosfomycin) which
are discussed in the text in detail.
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therefore, increase efficacy of penicillins to which this
strain should otherwise be resistant. In theory, this
means that the computational prediction that Piperacil-
lin/Tazobactam is effective should be correct. However,
it turns out that, in clinical practice, this drug is recom-
mended to be avoided due to possible inoculum effects.
Hence, the resistant flag from the clinical judgement
according to the used VITEK AES experimental classifi-
cation system.
The second case is Fosfomycin, to which the new
strain was experimentally found to be sensitive while the
computational approach assumed resistance due to the
identification of a multidrugefflux pump protein anno-
tated to also export Fosfomycin. This means that either
the annotation is inaccurate or it would be interesting to
further look into the detail of the few sequence differ-
ences between the new and the previously known trans-
porter (99% identity) to find determinants of activity and
substrate specificity which could be considered in a fu-
ture more comprehensive approach.
Overall, this crude workflow utilizing available data-
bases shows that a computational antibiotics susceptibil-
ity profile can be derived with some accuracy by
combining next generation genome sequencing with fur-
ther computational analysis, but it definitely still needs a
critical experienced doctor who further scrutinizes and
selects the most suitable treatment according to the cir-
cumstances of the infected patient as well as includes
any new clinical findings on drug responses of the re-
spective strain.
Bacterial communication and cooperation in health and
disease
The analysis of human microbiomes and small bacterial
communities causing multi-bacterial diseases are among
the most challenging and intriguing tasks of medical
genome research today [59-61] also including the field
of plant diseases [62]. The discovery of chemical com-
munication among bacteria in the 1990s has fundamen-
tally changed the traditional view that pictures bacteria
as single-celled organisms living in isolation [63-66]. In
the last fifteen years, it has become increasingly evident
that bacteria have the potential to establish highly com-
plex communities. Many microbes live in large, multi-
species communities in which the participants jointly
exploit the resources. Multispecies microbial consortia
constitute a major form of life that is found in environ-
ments ranging from high-altitude mountains (more than
8 km above sea level) to more than 10 km below the sur-
face of the oceans, and have always been among the
most important members and maintainers of the planet's
ecosystem. The medical importance of this phenomenon
is sweeping. Opportunistic pathogenes, such as Pseudo-
nomas and Burkholderia species abound in hospital
environments, ready to attack patients weakened by dis-
ease or injury. For instance, Pseudomonas aeruginosa
usually does not harm a healthy human organism, but
can be lethal in the lung of cystic fibrosis (CF) patients,
or in burn wounds [67].
Many prokaryotes possess inter-cellular signaling sys-
tems which allow species to colonise new habitats, to in-
vade hosts and to spread over surfaces [63-66]. A typical
example is quorum sensing (QS) which enables bacteria
to switch from low activity to high activity regimes using
signaling molecules as well as “public goods” (e.g. surfac-
tants, enzymes, siderophores) that facilitate movement,
nutrient uptake amongst other things [65,66]. We share
the widespread opinion that the “change of bacterial life-
style” is crucial for colonizing habitats and infecting sus-
ceptible hosts – unfortunately the signalling systems that
orchestrate the underlying communication and collabor-
ation mechanisms are not accurately annotated in bacter-
ial genomes. Therefore, a systematic characterization of
QS systems in Gram negative bacteria was carried out
[68,69] and a modelling effort to map out the theoretic-
ally possible consequences of communication and collab-
oration in bacterial populations was initiated [70-72].
Virulence and adaptability of many Gram-negative bac-
terial species are associated with an N-acylhomoserine
lactone (AHL) gene regulation mechanism called
quorum sensing (QS). The arrangement of quorum sens-
ing genes is variable throughout bacterial genomes, al-
though there are unifying themes that are common
among the various topological arrangements. A bioinfor-
matics survey of 1403 complete bacterial genomes
revealed characteristic gene topologies in 152 genomes
that could be classified into 16 topological groups
[68,69]. A concise notation for the patterns was devel-
oped and it was shown that the sequences of LuxR regu-
lators and LuxI autoinducer synthase proteins cluster
according to the topological patterns.
The macroscopic behavior of bacterial communities is
notoriously difficult to study, colony patterns, invasion/
colonization events depend on a multitude of parameters
many of which cannot be reproduced in lab cultures.
Therefore, computational modeling, and particularly the
use of simplified minimal models is a very important tool
for studying the behavior of populations in rational
terms. Agent-based models of communicating and col-
laborating bacteria have developed [70]. The bacterial
cells are represented by agents randomly moving on a
plain (such as an agar surface), while consuming nutri-
ents, secreting signal molecules and “public goods”.
Nutrients, signals and public goods are diffusing on the
surface, and their local concentration exceeds a thresh-
old, the metabolism and movement of bacterial agent
switches to a more intensive state. In this model signals
are the means of communications, and public goods are
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the means of cooperation as can be observed in QS bac-
teria. Even though highly simplified, the model reflects
the crucial behavior patterns of communicating/cooper-
ating bacteria in an open, nutrient/limited environment.
Namely, 1) isolated bacteria cannot survive; only bacteria
reaching a critical population size (“quorum”) have a
chance for survival. 2) Bacteria self-organize into com-
pact communities or “active zones” in which signals and
public goods are present in sufficient amounts [70]. 3) Col-
laborating communities can collapse if non-cooperating
mutants are present [71,72].
Modeling the mutants of QS mechanisms is highly
relevant for disease prevention. There is a very vivid
interest from the pharmaceutical and pesticide indus-
tries, analysts agree that interventions targeting quorum
sensing are among the major trends of the future. Since
many bacteria use quorum sensing for infection, it is
plausible to think about jamming strategies. According
to one such scenario, one can saturate the surface of a
plant with a signal molecule that will call bacteria to at-
tack. If a lonely pathogen lands on the surface, it will im-
mediately start to attack, but at the wrong time and
place. Since it is alone, it will perish. Or, we can put a
gene into the plant that produces an enzyme capable of
destroying the signal molecule of the pathogenic bac-
teria, so that those will never wage an attack. But both
strategies can strike back since they can also destroy the
signaling of the beneficial bacteria that are essential to
the host. According to a third scenario one may pre-
vent the growth of an infecting pathogen by a greedy
but antibiotic sensitive mutant of the same species,
and then we eliminate the mutant by an antibiotic that
specifically acts on that mutant. This is very appealing,
but what do we do if the mutant created to heal gets
some harmful genes or looses its antibiotic susceptabil-
ity? Many similar questions can be studied using com-
putational models [73].
Impact of bioimage informatics on healthcare
Most likely, the penetration of automated evaluation
tools for the analysis of clinically relevant histological
images in diagnostic contexts is one of the areas that will
experience great changes in the near future. The process
of biomedical imaging involves little or no discomfort to
the patients, while providing an effective tool for diagno-
sis. However, successful usage of images requires a high
level of human intelligence, making automated image
analysis by machines a challenging task. Currently, the
gold standard for diagnosis through imaging is by experi-
enced clinicians, typically radiologists or pathologists. It
takes many years to train proficient clinicians to analyze
images manually and, despite that, this gold standard is
not perfect and suffers from subjective variations be-
tween different clinicians.
Advances in image processing, pattern recognition and
computer vision in the past decades have boosted the
possibilities for the application of computing technology.
Currently, the focus is on computer aided diagnosis ra-
ther than to achieve a fully automated approach. Soft-
ware that can support decision making and reduce the
workload of clinicians, especially in routine operations, is
extremely useful and valuable. Besides the direct deriv-
ation of clinically relevant conclusions from the images,
such systems call also for the integration with databases
of medical ontologies, the patients’ medical records, etc.
Computational image analysis methods can be broadly
categorized into those used for assessment, diagnosis
and surgery. This section attempts to cover several ex-
emplary areas of imaging and image analysis in health-
care. Because of the large extent of research work
ongoing in academic bioimage informatics and medical
image analysis and the growing engagement of the in-
dustry, this section cannot be comprehensive but rather
we seek to cover a broad spectrum.
Digital pathology
Advances in computer vision and microscopy instru-
mentation have made digital pathology an important
emerging field. The objective is to aid the pathologist in
the analysis of high resolution cellular images obtained
through biopsy. For example, highlighting regions of
interest or reducing diagnostic variation can generate a
big impact. Histological images from various organs
such as prostate [74], breast [75] and liver have been the
object of algorithm development.
Here, we shall focus our discussion on prostate digital
pathology. Prostate cancer has a high prevalence rate
worldwide. For example, it is the most common non-
cutaneous male cancer in the United States [76] and it is
the 3rd most common male cancer in Singapore [16].
The American Cancer Society report in 2009 estimates
192,280 new prostate cancer cases with 27,360 prostate
cancer specific death [76]. The severity of prostate can-
cer diagnostics is compounded by disagreements be-
tween individual pathologists with regard to grading
using the Gleason classification [77]. This agreement be-
tween different pathologist can be as low as 70% [78]
and up to 29% of Gleason gradings were different be-
tween pre- and post-operative prostate cancer specimen
[79]. Hence, having objective computer algorithms to aid
in prostate pathology assessment is essential to improve
diagnosis.
Most computational methods are developed to analyze
microscopy images on the standard hematoxylin/eosin
stain. The goals are gland segmentation since the archi-
tecture of glands is critical for Gleason grading and the
identification and segmentation of nuclei since this is
useful for detecting nuclei signatures specific to
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cancerous cells. Common computer vision techniques
used are level sets [80], fractal analysis [81] and machine
learning [80,82-86]. These techniques are used to seg-
ment glands [80,85] and nuclei [82,84] or to identify
regions of malignancy directly [83].
Computer vision in dermatology
Assessment of skin condition and health is both import-
ant for clinical medicine as well as for the cosmetics in-
dustry. At present, assessment of the skin typically
involves a trained dermatologist who will examine fea-
tures such as textures and landmarks. While training of
dermatologists takes many years, the subsequent diagno-
sis suffers from subjective interpretation differing among
dermatologists. Hence, a more objective approach is in
demand.
Considerable effort is ongoing to analyze skin surfaces
through the use of objective computational methods.
Protocols to ensure objective and consistent imaging of
human skin (for example, in a well-controlled lighting
environment) are vital for reliable diagnosis by computer
algorithms [87-89]. Image acquisition is followed by the
application of task-dependent image processing and
computer vision methods. Liu et al. [90] use texture
analysis to create an objective way of evaluating the ef-
fectiveness of treatment. A neural network framework
has been developed to analyze the human skin condi-
tions such as color, roughness, glossiness or tension
[91,92]. Skin images have also been studied with data
mining methods [88,93] and via modeling/reconstruct-
ing the skin surface [89,94].
Computer vision in eye diseases
Imaging methods for eye diseases are unique among bioi-
maging techniques because images of the eyes are easily
accessible using conventional light cameras. There is no
need for expensive and sophisticated machines such as a
computer tomograph or magnet resonance imager. A
common imaging modality is the optical coherence tom-
ography; other imaging methods such as fundus photog-
raphy, ultrasound and infra-red imaging are also used.
Although image analysis has been used in the assessment
of many eye diseases, we will focus our discussion on
glaucoma and dry eye disease in this paper.
Angle closure glaucoma
According to a world health organization report [95],
glaucoma is a major global cause of blindness (approxi-
mately 5.2 million cases and about 15% of all cases of
blindness). The impact of glaucoma on public health will
increase with an aging population. However, the lack of
a comprehensive measure of glaucoma compounded
with its ability to cause sudden blindness makes it hard
for treatment planning. Surprisingly, about 50-90% of
potential patients in the world are unaware that they
have glaucoma [96,97].
Glaucoma is classified into angle closure and open
angle glaucoma according to the drainage angle, the
angle between the cornea and iris. Primary angle closure
glaucoma is the major form of glaucoma in Asia, in par-
ticular, among the Chinese population. It was suggested
that angle closure glaucoma causes more blindness than
open angle glaucoma in relative terms [98].
A common way for assessment of angle closure glau-
coma is through gonioscopy in which the doctor uses an
optical instrument to look at the anterior chamber to de-
cide if the drainage angle is open or close. Ultrasound
[99] and optical coherence tomography (OCT) [100]
images are also used for assessment. Computer vision
techniques are used for analyzing eye images derived
from the different modalities. As it takes much effort to
master the technique of gonioscopy, Cheng et al. [101]
developed a computational technique for RetCam
images. A machine-learning based method aids glaucoma
diagnosis by analyzing the cup-to-disc ratio measured
on fundus images [102]. OCT images provide high
resolution and a 3D view of the anterior chamber.
Image analysis software has been developed to make
precise measurements of important geometric informa-
tion such as anterior chamber area, anterior chamber
width, iris thickness, etc. on OCT images [103]. These
data can then be correlated to generate new clinical
knowledge [104,105].
Image analysis in assessing the dry eye condition
The disease of dry eye has no clear definition; generally,
it is a condition in which there is an unstable tear film
during the open eye state. The dry eye condition has a
prevalence rate of 10-20% in Sweden, Japan, Australia
and several other countries. The most common treat-
ment of dry eye is application of eye drops [106].
One cause of dry eye disease is meibomian gland dys-
function. The meibomian glad is located at the inside of
the tarsel plate that supplies meibum, an oily substance,
which forms a protective layer to the tear film. Dysfunc-
tion of meibomian glands causes lack of meibum and,
often, resulted in degeneration of meibomian glands.
The morphology of meibomian glands can be imaged
using an infra-red camera mounted on a conventional
slit lamp camera [106]. This imaging technology has
enabled the application of advanced computer vision
techniques for better diagnosis and patient management.
Images from healthy meibomian glands shows a strip
like pattern in gland morphology; with the strips being
relatively straight, parallel and equally spaced. Images of
highly degenerated glands show no strip like patterns at
all, but only small isolated regions of remnant glands.
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Morphology for early stage disease shows twisting, non-
parallel and unequally spaced strip like patterns [106].
While the process of imaging is simple and relatively
cheap, the analysis of the morphology of meibomian
glands and other clinical examinations that eventually
lead to diagnosis and treatment require trained ophthal-
mologists with experience in handling dry eye patients.
Unfortunately, there is no clear objective criteria for
grading meibomian glands morphology degeneration, al-
though some schemes have been suggested [106]. Inter-
individual variation will also cause problems. Hence,
large population screens on meibomian glands morph-
ology does not directly lead to overall increase in better
management of the disease.
An effective way to circumvent the problem of cost
and inter-individual variation is to develop advanced
computer vision techniques to process and grade images
of meibomian glands. A team from Singapore has devel-
oped an image analysis software that can enhance infra-
red images of meibomian glands, segment the strip-like
patterns and extract important features for classifying
the images [107].
Image analysis for assisted surgery
Pre-planning is an important component to the success
of surgery, so that surgical operations can be performed
systematically, completely and swiftly. Usually, planning
involves studies of 3D images of the part of the patient’s
body where the operation will be performed. Image
assisted surgery is available or being developed for al-
most all parts of the human body, for example for brain,
liver, heart, gastrointestinal tract and for hand recon-
struction surgery. The digital 3D image is enhanced by
advanced computer graphics, visualization and various
forms of accurate geometrical measurements done by
the computer. This enhancement is very important be-
cause the human mind cannot decipher 3D objects
represented on a 2D computer screen effectively. We are
also unable to make accurate geometrical measurements.
In this case, the computer essentially provides the “ruler”
to make measurements.
Tumor segmentation
Accurate measurements are particularly important in
the case of surgery aimed at removing tumors. The size
of the tumor is an important prognostic factor for treat-
ment. 1D and 2D measurements such as tumor length,
the largest axis length or cross sectional area had been
used as a measure of tumor sizes. However, studies have
shown that tumor volume provides a more accurate esti-
mate of the tumor size [108,109]. Accurate measurement
of tumor sizes calls for effective segmentation of tumors.
Once properly segmented, the tumor size can be calcu-
lated trivially. Tumors occur in many parts of the human
body and different segmentation algorithms are devel-
oped for segmenting tumors in different organs. The lit-
erature in this area is vast. In the following, we focus on
liver tumors. Liver cancer accounts for about one mil-
lion deaths per year [110]. Segmentation is usually done
on computer tomography images. Many techniques have
been developed to segment liver and its tumor including
region growing [109,111], statistical techniques [109],
machine learning [108,109], active contours [112], fuzzy
c-means [113] and watershed [114].
Surgery planning also needs careful consideration of
the vasculature structure around the tumor and their re-
lationship with the tumor. Hence, segmentation of the
vasculature structure can aid the surgeon to visualize the
structure and location of vessels [115].
Concluding remarks
The development and implementation of analytical
and computational tools provided from the side of
bioinformatics and bioimaging analysis provide op-
portunities for quality interaction among biotechnol-
ogy, fundamental life science research and clinical
studies. Bioinformatics findings can be translated into
innovations that are adopted by the healthcare sys-
tem and biomedical industry in form of diagnostic
kits, analysis programs, etc. after the validation in
both bench and clinical studies. In this article, we
present several examples of how clinically relevant
conclusions can be drawn from sequencing, expres-
sion profiling or histopathological bioimaging data
with computational biology algorithms.
Unfortunately, considerable basic research is still
necessary to make full use of the potential opportun-
ities that are associated with the increasing availabil-
ity of high-throughput technologies such as genome
sequencing, mainly since most of the genome’s hid-
den functional information is not known; the under-
standing of biomolecular mechanisms that translate
genotype into phenotype is limited. But the progress
in this field is uneven; pathogen sequencing can
already provide important insights in contrast, for
example, to sequencing of cancer samples.
Since an efficient healthcare system must be
aligned to social, economic and political infrastruc-
ture of the country and focus on evidence-based
prophylactic, prevention, diagnosis, prognosis, predic-
tion and treatments that are proven to provide qual-
ity service and clinical outcome in a cost-effective
manner, genomics, proteomics and other new tech-
nologies will first have to demonstrate in a research
hospital setting that they can have a dramatic effect
in improving health care, also cost-wise in addition
to providing better quality of life, before the
approaches will penetrate the routine healthcare
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systems. Nevertheless, it is very clear that major
advances in diagnostics and treatments for infections
as well as cancers, circulatory and metabolic diseases
that are critical for improving most healthcare sys-
tems will arise from these developments in a medium
to longer time frame.
As we have seen above, genome information of patho-
gens linked with the geographic origin allows tracing the
spread of infections and parasites. Similarly, analyzing
the geographic, even better spatio-temporal distribution
of disease occurrences can provide hints for environ-
mental influences [116,117]. Generally, going beyond the
patient-centric approach and the linking of biomolecular
and clinical data of populations with geographic infor-
mation, data on food and environment, etc. will be an
important source for improving public health, for stop-
ping epidemics, for finding sources of food or environ-
mental poisoning and for improving life styles.
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